CHD-5
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H558387

CAS#: 289494-16-2

Description: CHD-5 is selective aryl hydrocarbon receptor (AhR) antagonist.

Chemical Structure

img
CHD-5
CAS# 289494-16-2
Instruction

Theoretical Analysis

Hodoodo Cat#: H558387
Name: CHD-5
CAS#: 289494-16-2
Chemical Formula: C19H17N3O2
Exact Mass: 319.13
Molecular Weight: 319.360
Elemental Analysis: C, 71.46; H, 5.37; N, 13.16; O, 10.02

Price and Availability

Size Price Availability Quantity
5mg USD 280
25mg USD 670
Bulk inquiry

Synonym: CHD-5; CHD 5; CHD5;

IUPAC/Chemical Name: Furan-2-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide

InChi Key: RDQWQMVBBQKHGH-QURGRASLSA-N

InChi Code: InChI=1S/C19H17N3O2/c1-13-6-3-4-7-17(13)22-21-15-9-10-16(14(2)12-15)20-19(23)18-8-5-11-24-18/h3-12H,1-2H3,(H,20,23)/b22-21+

SMILES Code: O=C(C1=CC=CO1)NC2=CC=C(/N=N/C3=CC=CC=C3C)C=C2C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 319.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Higashi M, Kolla V, Iyer R, Naraparaju K, Zhuang T, Kolla S, Brodeur GM. Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma. Mol Cancer. 2015 Aug 7;14:150. doi: 10.1186/s12943-015-0425-y. PubMed PMID: 26245651; PubMed Central PMCID: PMC4527355.

2: Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur GM. Role of CHD5 in human cancers: 10 years later. Cancer Res. 2014 Feb 1;74(3):652-8. doi: 10.1158/0008-5472.CAN-13-3056. Epub 2014 Jan 13. Review. PubMed PMID: 24419087; PubMed Central PMCID: PMC3965582.

3: Kolla V, Naraparaju K, Zhuang T, Higashi M, Kolla S, Blobel GA, Brodeur GM. The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. Biochem J. 2015 Jun 1;468(2):345-52. doi: 10.1042/BJ20150030. PubMed PMID: 25825869; PubMed Central PMCID: PMC4487910.

4: Bishop B, Ho KK, Tyler K, Smith A, Bonilla S, Leung YF, Ogas J. The chromatin remodeler chd5 is necessary for proper head development during embryogenesis of Danio rerio. Biochim Biophys Acta. 2015 Aug;1849(8):1040-50. doi: 10.1016/j.bbagrm.2015.06.006. Epub 2015 Jun 17. PubMed PMID: 26092436; PubMed Central PMCID: PMC4544782.

5: Egan CM, Nyman U, Skotte J, Streubel G, Turner S, O'Connell DJ, Rraklli V, Dolan MJ, Chadderton N, Hansen K, Farrar GJ, Helin K, Holmberg J, Bracken AP. CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev Cell. 2013 Aug 12;26(3):223-36. doi: 10.1016/j.devcel.2013.07.008. PubMed PMID: 23948251.

6: Li W, Wu J, Kim SY, Zhao M, Hearn SA, Zhang MQ, Meistrich ML, Mills AA. Chd5 orchestrates chromatin remodelling during sperm development. Nat Commun. 2014 May 13;5:3812. doi: 10.1038/ncomms4812. PubMed PMID: 24818823; PubMed Central PMCID: PMC4151132.

7: Liu JB, Zhou QB, Xu JZ, Wang GX, Yuan WT. Influence of colorectal cancer tumor suppressor gene CHD5 methylation on its clinical and pathological characteristics. J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):889-93. PubMed PMID: 26753653.

8: Zhao R, Meng F, Wang N, Ma W, Yan Q. Silencing of CHD5 gene by promoter methylation in leukemia. PLoS One. 2014 Jan 13;9(1):e85172. doi: 10.1371/journal.pone.0085172. eCollection 2014. PubMed PMID: 24454811; PubMed Central PMCID: PMC3890315.

9: Zhao R, Wang N, Huang H, Ma W, Yan Q. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma. Liver Int. 2014 Jul;34(6):e151-60. doi: 10.1111/liv.12503. Epub 2014 Mar 15. PubMed PMID: 24529164.

10: Quan J, Adelmant G, Marto JA, Look AT, Yusufzai T. The chromatin remodeling factor CHD5 is a transcriptional repressor of WEE1. PLoS One. 2014 Sep 23;9(9):e108066. doi: 10.1371/journal.pone.0108066. eCollection 2014. PubMed PMID: 25247294; PubMed Central PMCID: PMC4172601.

11: Xie CR, Li Z, Sun HG, Wang FQ, Sun Y, Zhao WX, Zhang S, Zhao WX, Wang XM, Yin ZY. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma. Oncotarget. 2015 Dec 1;6(38):40940-52. doi: 10.18632/oncotarget.5724. PubMed PMID: 26517514; PubMed Central PMCID: PMC4747380.

12: Hall WA, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Oncogene. 2014 Nov 20;33(47):5450-6. doi: 10.1038/onc.2013.488. Epub 2013 Nov 25. PubMed PMID: 24276239.

13: Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H, Ashktorab H. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer. 2014 Jan 15;120(2):172-80. doi: 10.1002/cncr.28316. Epub 2013 Nov 14. PubMed PMID: 24243398; PubMed Central PMCID: PMC3947327.

14: Bergs JW, Neuendorff N, van der Heijden G, Wassenaar E, Rexin P, Elsässer HP, Moll R, Baarends WM, Brehm A. Differential expression and sex chromosome association of CHD3/4 and CHD5 during spermatogenesis. PLoS One. 2014 May 21;9(5):e98203. doi: 10.1371/journal.pone.0098203. eCollection 2014. PubMed PMID: 24849318; PubMed Central PMCID: PMC4029951.

15: Zhuang T, Hess RA, Kolla V, Higashi M, Raabe TD, Brodeur GM. CHD5 is required for spermiogenesis and chromatin condensation. Mech Dev. 2014 Feb;131:35-46. doi: 10.1016/j.mod.2013.10.005. Epub 2013 Nov 16. PubMed PMID: 24252660; PubMed Central PMCID: PMC3965579.

16: Paul S, Kuo A, Schalch T, Vogel H, Joshua-Tor L, McCombie WR, Gozani O, Hammell M, Mills AA. Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep. 2013 Jan 31;3(1):92-102. doi: 10.1016/j.celrep.2012.12.009. Epub 2013 Jan 10. PubMed PMID: 23318260; PubMed Central PMCID: PMC3575599.

17: Ma Z, Song J, Liu S, Han L, Chen Y, Wang Y, Yu C, Hou L. Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation. Oncol Lett. 2016 Nov;12(5):4021-4026. Epub 2016 Sep 16. PubMed PMID: 27895765; PubMed Central PMCID: PMC5104224.

18: Quan J, Yusufzai T. The tumor suppressor chromodomain helicase DNA-binding protein 5 (CHD5) remodels nucleosomes by unwrapping. J Biol Chem. 2014 Jul 25;289(30):20717-26. PubMed PMID: 24923445; PubMed Central PMCID: PMC4110282.

19: Wang L, He S, Tu Y, Ji P, Zong J, Zhang J, Feng F, Zhao J, Gao G, Zhang Y. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma. J Clin Neurosci. 2013 Jul;20(7):958-63. doi: 10.1016/j.jocn.2012.07.021. Epub 2013 May 23. PubMed PMID: 23707602.

20: Yu L, Gong X, Sun L, Yao H, Lu B, Zhu L. miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma. Oncotarget. 2015 Nov 17;6(36):39225-34. doi: 10.18632/oncotarget.4407. PubMed PMID: 26287602; PubMed Central PMCID: PMC4770768. ^